COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

7 results for "Cancer" and "Eye/Orbital Cancers" and "Lymphoma"

A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

The purpose of this clinical research study is to identify an appropriate safe dose of JBH492 that can be given to patients with NHL or CLL who did not improve after treatment with currently available therapies, have had their disease worsen, and/or cannot tolerate currently available therapies. This study will also evaluate how well JBH492 might work in treating your disease and will give us an understanding how your body responds to the study treatment. In order to achieve this, a number of blood and tissue samples will be collected during the study.
Protocol No
NOVARTIS-CJBH492A12101
Sub Category
Early Phase/Multiple Disease Site Cancers

A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

This is a Phase 1, First-in-Human clinical trial, meaning that it is the first study where TNB-486 will be given to humans. This study is open-label, meaning that everyone on the study will receive study drug, at various doses.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Protocol No
ACCRU-SC-1601
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers

A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.
Protocol No
CYTEIR-CYT-0851-01-REFMAL639
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Sarcoma, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers